BioLine RX Market capitalization
The The market capitalization of BioLine RX (BLRX.TA) as of Sep 3, 2026 is 11.78 M USD. In the previous year, The market capitalization was 11.78 M USD — a change of 0.00% (lower).
Get this data via API
Financial Data API
Market capitalization
11.78 MUSD
YoY
0.00%
Last updated:
In 2026, BioLine RX's market cap stood at 11.78 M USD, a 0.00% increase from the 11.78 M USD market cap in the previous year.
The BioLine RX Market capitalization history
3 Years
10 Years
25 Years
Max
| YEAR | Market capitalization | YoY |
|---|---|---|
| 11.78 MUSD | 0.00% | |
| 11.78 MUSD | 0.00% | |
| 11.78 MUSD | 0.00% | |
| 11.78 MUSD | 0.00% | |
| 11.78 MUSD | 0.00% | |
| 11.78 MUSD | 0.00% | |
| 11.78 MUSD | 0.00% | |
| 11.78 MUSD | 0.00% | |
| 11.78 MUSD | 0.00% | |
| 11.78 MUSD | 0.00% | |
| 11.78 MUSD | — |
BioLine RX Stock analysis
Market capitalization Details
Exploring BioLine RX's Market Capitalization
BioLine RX's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.
Year-to-Year Comparison
A yearly comparison of BioLine RX's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.
Impact on Investments
BioLine RX's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.
Interpreting Market Capitalization Fluctuations
Variations in BioLine RX’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.
Frequently Asked Questions about BioLine RX stock
The market capitalization of BioLine RX is 11.78 M USD in 2026.
The market capitalization of BioLine RX changed from 11.78 M USD to 11.78 M USD, representing a 0.00% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of The market capitalization BioLine RX since 2006 – with annual values, charts, and detailed analysis.
Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.
Number of shares * share price = market capitalization
To evaluate The market capitalization's USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.
A 'good' USD varies by industry and company stage. On Eulerpool, you can compare The market capitalization's BioLine RX with sector peers and the industry average to assess whether it is attractive.
Valuation — BioLine RX
All Key Metrics — BioLine RX
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth